Vision

Vision & Ocular Health Stack

Age-related vision decline shares the same biological drivers as other aging processes — vascular insufficiency, oxidative damage, and reduced growth factor signaling — and this stack addresses all three. BPC-157 stimulates angiogenesis in avascular ocular tissue and modulates the inflammation driving most progressive eye conditions; TB-500 promotes photoreceptor and RPE cell renewal through actin expression and microvascular support; and Epithalon provides the cellular senescence intervention that retinal aging ultimately represents. For dry eye or surface conditions, BPC-157 can be formulated as sterile eye drops by a compounding pharmacy — never attempt this at home.

Intermediate 8 week cycle 3 peptides Save
For educational and research purposes only. Not medical advice. This protocol describes research use, not human administration. Always consult a qualified professional.

Protocol & Dosing

Primary Protocol (5 days on / 2 days off):

  • BPC-157: 250 mcg subcutaneously daily
  • TB-500: 2.5 mg subcutaneously twice weekly
Epithalon Pulse (twice per cycle):
  • Epithalon: 5–10 mg subcutaneously daily for 10 consecutive days (weeks 1–2 and 5–6)
Cycle: 8 weeks on / 4 weeks off

Notes: For dry eye or surface-level conditions, BPC-157 can be formulated as eye drops (requires compounding pharmacy with sterile formulation). Do not attempt to prepare injectable peptides as eye drops at home — sterility is critical. Pair with lutein, zeaxanthin, omega-3 DHA, and blue-light blocking strategies throughout the cycle. Annual eye examination recommended before and after cycle.

Calculate Doses for This Stack

Use the Peptide Oracle calculator to get exact BAC water ratios and draw amounts for every peptide in this protocol.

Open Dosage Calculator